


Five Days in May: COVID-19 Edition



Educate. Inform. Inspire. Stimulate. After last year's hiatus, Five Days in May is back! This year's edition of Island Health's research showcase is online and focused on key COVID research initiatives. Join us to hear the latest in vaccine development, how COVID 19 has shaped public health research priorities, and more. Details and registration at islandhealth.ca/fivedays

► Congratulations to the Evidence-into-Practice Award Winners

GOLD: Rapid Triage and Diagnosis of Complex Regional Pain Syndrome I and II; Halting Long Term Disability

Dr. Paul Winston (Medical Director, Rehabilitation and Transitions)

SILVER: Hospital at Home (HaH)

Dr. Sean Spina (Principal Investigator – ATHOME; HaH Clinical Subject Matter Expert);

Dr. Elisabeth Crisci (Hospitalist, Medical Co-Lead with HaH); **Dr. Shauna Tierney** (Hospitalist, Medical Co-Lead with HaH)

BRONZE: The Victoria Enhanced Recovery Arthroplasty Program (VERA)

Dr. Duncan Jacks (Orthopedic Surgeon); **Dr. Jacques Smit** (Anesthesiologist)


► NRGH's clinical research team leads enrollment in global trial

Last fall, the newly minted Nanaimo-based clinical research team enrolled their first patient in the global clinical trial REVISE (Re-Evaluating the Inhibition of Stress Erosions and prophylaxis against gastrointestinal bleeding in the critically ill.) Now, just five months later, the team at Nanaimo Regional General Hospital are the highest enrollers in the global study when sites are pro-rated by ICU size and average monthly enrolment is indexed to a 15-bedded unit. NRGH is one of 30 sites in Canada.

Join NRGH and RJH clinical research teams for their Five Days in May presentation [Clinical Trials: Stops, Pivots & Strides during a Pandemic](#) and learn how Island Health initiated and expanded access to COVID-19 trials while continuing to focus on participants enrolled in non-COVID trials.

► Vancouver Island Biobank Update

The biobank is now housing over 300 biospecimen from COVID-19 patients. The specimen were collected from COVID-19 patients while being treated in the ICU and will be used in quality improvement and research projects.



Active Studies in Cowichan Valley Region and island-wide

	Project Title	Principal Investigator	Sites	
	This list shows new studies approved October 1 2020 - March 31, 2021.			
New	BC Healthy Connections Project: A Scientific Evaluation of the Nurse-Family Partnership Program in British Columbia	Waddell Charlotte	all	
New	Cultural safety study ~ Planning and Developing a Culturally Safe Framework for Engaging Immigrant and Refugees in Mental Health Research	Clark Nancy	all	
New	Inguinal Hernia Pain Survey ~ Post-operative pain after open inguinal hernia repair – a single-centred retrospective study	Truter Andre	SPH	Cowichan
New	Determine ~(BoR BC Cancer Association)	Saltman David	RJH, VGH, SPH	Cowichan
New	Care during COVID-19 study ~ A study of patients’ perspectives on the impact of COVID-19 on the care and support for British Columbians living with asthma and COPD	Carlsten Christopher	RJH, VGH, CDH, NRGH, CRH	COVID-19 Cowichan
New	IN-PoCUS Profiling and Prognosticating COVID-19 patients Using Big Data: A Pan-Pop-BC Data Artificial Intelligence Study	Tsang Teresa S. M.	all	COVID-19
New	iOAT ~ Observational Prospective Study of Injectable Opioid Agonist Treatment	Fairbairn Nadia	all	
New	RAFT Long-Term ~ Long-Term Outcomes of the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT)	Sterns Laurence	all	
New	The PREVENT-COVID Study: PRospEctiVe EvaluationN of immuniTy after COVID-19 vaccines	Sadarangani Maish	all	COVID-19
New	A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma (CheckMate 76K) Protocol Number: CA20976K (BCCA BoR)	Metcalf Corey	all	
New	CANVAS Surveillance of Adverse Events Following Immunization among Individuals Immunized with the COVID19 Vaccine	Bettinger Julie	all	COVID-19
New	LA LEAST- Luminal A, Limited Endocrine Adjuvant Systemic Therapy, a phase II trial of abbreviated hormone therapy for low risk hormone receptor positive, HER2 negative early breast cancer (BCCA BoR)	Lohrisch Caroline	all	